Company's next-generation EMR platform, Nexia™ EMR, to incorporate PEPID's electronic decision-support resources and the Canadian Pharmacists Association's drug information content
MARKHAM, ON, May 9, 2013 /CNW/ - Nightingale Informatix Corporation ("Nightingale" or the "Company") (TSX-V: NGH), a provider of cloud-based electronic medical record (EMR) software and related services, today announced that it has partnered with PEPID, a multi-national provider of electronic decision-support resources for healthcare professionals, to incorporate its Canadian drug reference tools into Nightingale's next-generation platform - Nexia™ EMR. As part of this agreement, Nightingale has also established a partnership with the Canadian Pharmacists Association ("CPhA"), which publishes Canada's trusted bilingual drug reference, the Compendium of Pharmaceuticals and Specialties (CPS), to incorporate their drug information into Nexia™ EMR.
As a result of these partnerships, Nexia™ EMR will offer users real-time access to a comprehensive set of clinical decision support tools for medication management. Additionally, practitioners will have access to a trusted set of evidence-based drug information in both English and French.
"With its intuitive functionality, cloud-based access and seamless ability to integrate with third-party tools and information, we believe Nexia™ EMR will be a disruptive force in the North American EMR marketplace," said Sam Chebib, President & CEO of Nightingale. "Partnering with these two leading organizations is an important element in our strategy to develop a truly differentiated next-generation EMR offering. Our more comprehensive Nexia™ EMR platform can enhance patient care and safety, as well as bring additional benefits to the healthcare provider in terms of process and efficiency."
Through Nexia™ EMR, healthcare providers will have access to PEPID's clinical decision-support tools that inform them of potential drug interactions, duplicate therapy and potential contraindications with laboratories, pregnancy and medical conditions, at the point-of-care. In addition, the drug monographs and patient handouts from the CPhA will enable Nightingale's clients to stay current on the latest news on medication, helping to ensure a high level of patient safety.
"I'm proud Nightingale has chosen PEPID as their decision-support partner," said John Wagner, PEPID president. "PEPID delivers comprehensive, instantly accessible point-of-care reference materials so that healthcare providers are able to offer faster, safer and more effective care wherever they are - whether it's in a hospital, in their clinic, on the road or in a disaster zone. Nightingale's Nexia™ EMR clients can be confident that their prescribing decisions have been checked against the most authoritative resource available."
"It is clear that Nightingale is leading the charge in Canada, when it comes to integrating medication safety tools into an EMR solution," said Dr. James de Gaspé Bonar, Senior Director, Digital Publishing Solutions at CPhA. "The synergy between our organizations was apparent very early on. Nightingale's team is committed to patient safety and is eager to integrate industry-leading information sources, like ours, into their application. We are looking forward to collaborating with Nightingale on other initiatives as our relationship evolves."
Nightingale is one of the fastest growing health care service and software companies in North America and is recognized as an industry leader in Web-based clinician and community based electronic medical records (EMR) serving the needs of small primary care practices, multi-physician outpatient clinics, and large scale regional health organizations and networks. Nightingale's comprehensive service offering allows customers to enhance patient care, increase revenue opportunities and optimize operations. Nightingale is continuously innovating and enhancing its services to meet the needs of its growing and diverse customer base. Nightingale - Healthcare connected. www.nightingalemd.ca
About PEPID LLC
PEPID utilizes mobile and online technology to deliver clinical decision-support resources specific for healthcare professionals including doctors, nurses, EMTs and students. PEPID content is reviewed and contributed to by partners including the American Academy of Emergency Medicine, the National Association of Emergency Medical Services Educators, the Family Physician Inquiries Network, the National Association of Clinical Nurse Specialists, the Oncology Nursing Society, and the American Society of Health-System Pharmacists to ensure content is of the highest quality. Learn more about PEPID at www.pepid.com or www.pepid.ca.
About the Canadian Pharmacists Association
The Canadian Pharmacists Association is the nonprofit organization that advocates for pharmacists in Canada. CPhA stays on the cutting edge of breaking news in health care and ensures that pharmacists are included in discussions on the changing health care landscape. CPhA publishes Canadian therapeutic and drug information in print, online and mobile formats, making it accessible to health care providers at point-of-care. Innovation, advocacy, education, information and collaboration are some of the major areas the CPhA focuses on to support pharmacists and advance the profession. CPhA puts the tools pharmacists need in their daily practice in their fingertips and develops innovative ways to help clinicians provide optimal patient-centred care. Find out more at www.pharmacists.ca.
Forward Looking Statement
This press release contains "forward-looking statements" respecting the issuance and cancellation of securities of the Company within the meaning of applicable Canadian securities legislation. Generally, forward-looking statements can be identified by the use of forward- looking terminology such as "plans", "expects" or "does not expect", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may" ,"could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Nightingale to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the speculative nature of the medical software industry, which is affected by numerous factors beyond Nightingale's control; the ability of Nightingale to successfully secure customer contracts and the timing of securing such contracts; the ability of Nightingale to complete and successfully integrate its acquisitions on an accretive basis, Nightingale's access to debt and capital facilities, including compliance with current debt arrangements; the existence of present and possible future government regulation; the significant competition that exists in the medical software industry; the early stage of Nightingale's business, and risks associated with early stage companies, including uncertainty of revenues, markets and profitability and the need to raise additional funding. All material assumptions used in making forward-looking statements are based on management's knowledge of current business conditions and expectations of future business conditions and trends. Certain material factors or assumptions applied by management in making forward-looking statements, include without limitation, factors and assumptions regarding future trends in healthcare spending, economic conditions affecting Nightingale and North American economies; Nightingale's ability to continue to fund its business, rates of customer defaults, relationships with, and payments to lenders, as well as Nightingale's operating cost structure.
Although Nightingale has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Nightingale does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities laws. Further information on Nightingale Informatix Corporation is available at www.sedar.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Nightingale Informatix Corporation
For further information:
For further information about Nightingale, contact:
Corporate Marketing Manager
Nightingale Informatix Corporation
Tel: 416-815-0700 ext. 273
For further information about PEPID, contact:
Tel: 888-321-7828 x211
For further information about CPhA, contact:
Director, Sales and Business Development
Canadian Pharmacists Association
Tel: 1-800-917-9489 ext. 233